Arcutis Biotherapeutics, Inc. Quarterly Operating Income (Loss) in USD from Q1 2019 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Arcutis Biotherapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2019 to Q3 2024.
  • Arcutis Biotherapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$39.1M, a 5.86% decline year-over-year.
  • Arcutis Biotherapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$182M, a 26.7% increase year-over-year.
  • Arcutis Biotherapeutics, Inc. annual Operating Income (Loss) for 2023 was -$241M, a 20.1% increase from 2022.
  • Arcutis Biotherapeutics, Inc. annual Operating Income (Loss) for 2022 was -$302M, a 46% decline from 2021.
  • Arcutis Biotherapeutics, Inc. annual Operating Income (Loss) for 2021 was -$207M, a 51.1% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$182M -$39.1M -$2.16M -5.86% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-06
Q2 2024 -$180M -$50.1M +$16.7M +25% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 -$196M -$31.6M +$44.6M +58.5% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 -$241M -$61.2M +$7.26M +10.6% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-27
Q3 2023 -$248M -$36.9M +$67.8M +64.8% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-06
Q2 2023 -$316M -$66.8M -$936K -1.42% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 -$315M -$76.3M -$13.6M -21.8% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 -$302M -$68.4M +$2.86M +4.02% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-27
Q3 2022 -$304M -$105M -$47.7M -83.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-03
Q2 2022 -$257M -$65.8M -$23.7M -56.4% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 -$233M -$62.6M -$26.5M -73.6% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 -$207M -$71.3M -$37.2M -109% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-27
Q3 2021 -$169M -$57.1M -$18.8M -49% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 -$151M -$42.1M -$6.45M -18.1% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 -$144M -$36.1M -$7.43M -25.9% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 -$137M -$34.1M -$21.1M -162% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-28
Q3 2020 -$116M -$38.3M -$23.7M -161% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$91.9M -$35.6M -$27.1M -317% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 -$64.8M -$28.7M -$21.7M -312% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 -$43.1M -$13M Oct 1, 2019 Dec 31, 2019 10-K 2022-02-22
Q3 2019 -$14.6M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$8.54M Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-11
Q1 2019 -$6.95M Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.